IND Swift Laboratories (INDSWFTLAB.NS) Stock Price

IND Swift Laboratories Price

CLOSED
365.20
​
Market closed

Revenue has compounded at 3.2% per year over the past 19 years to 6.41 B INR. Earnings per share have grown at 4.4% per year over the last 19 years. IND Swift Laboratories's net margin stands at 6.5%, up from -0.2% several years earlier. IND Swift Laboratories currently offers a dividend yield of about 0.27%. The payout ratio is around 16% of earnings.

IND Swift Laboratories stock price

Access this data via the Eulerpool API

IND Swift Laboratories business model & stock analysis

Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh and currently employs 1,496 full-time employees. The company went IPO on 2002-03-15. The firm is engaged in the business of manufacturing intermediates and formulations. The Company’s products or services include Advanced Intermediates. The company is API partner for many organizations both in generic and innovative domains. The firm offers reference standards and impurities for various active pharmaceutical ingredients (APIs) under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for supply. The firm offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories.

Frequently asked questions about IND Swift Laboratories

Converted at the current exchange rate, the IND Swift Laboratories share trades at 3.37 EUR (365.20 INR).

The revenue of IND Swift Laboratories is 6.41 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of IND Swift Laboratories is 414.15 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of IND Swift Laboratories is currently 76.57. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IND Swift Laboratories stock.

The price-to-sales ratio (P/S) of IND Swift Laboratories is currently 4.95. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IND Swift Laboratories stock.

The Eulerpool Quality Score for IND Swift Laboratories is 2/10.

The ISIN of IND Swift Laboratories is INE915B01019. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of IND Swift Laboratories is INDSWFTLAB.NS. The ticker symbol is used to trade IND Swift Laboratories shares on the stock exchange.

Fair ValueTerminal
303.12 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
4.29 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
Mar 15, 2002
ISIN
INE915B01019
Cusip
Y3990X106
Market capitalization
29.80 B INRLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
161.74
P/B Ratio
2.15
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
2.95 %
Dividend
Dividend yield
0.00 %
Payout Ratio
13.57 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
20.00 %
Last updated Oct 9, 2026, 9:23 PM

IND Swift Laboratories Peer Group

IND Swift Laboratories FIGI

ISL:IN · BBG000CDZQ10ISL:IB · BBG000CDZQQ3ISL:IS · BBG000CDZRN4ISL:IG · BBG003NW47G0